Michael B. Lilly, MD is a noted translational cancer researcher and urologic oncologist. He is Associate Director for Translational Research at MUSC's Hollings Cancer Center. Dr. Lilly also sees patients with advanced prostate cancer at Hollings and the Ralph H. Johnson VA Medical Center.
Dr. Lilly is a recognized expert in the field of targeted therapeutics. Specifically, he has focused on stress response pathways that are triggered in cancer cells and which contribute to resistance to cancer therapy. Many stresses (including the stresses generated by cancer treatment) lead cells to activate defense pathways that allow them to survive the stress.
Dr. Lilly holds significant funding from the US Department of Defense and the biotech industry. His lab established Hollings as the headquarters of a nationwide consortium to carry out a clinical trial in men with castration-resistant prostate cancer previously treated with chemotherapy. His team, in collaboration with UCLA, works to identify additional ways of improving outcomes for those patients.
Dr. Lilly, a professor of Medicine, was recruited in 2012 from the University of California, Irvine, where he served as vice chief for Clinical Programs in the Division of Hematology/Oncology. He also served as co-leader for the Translational Oncology Program and the Prostate Translational Working Group. Prior to his tenure at the University of California, Irvine, Lilly spent eight years at the Loma Linda University School of Medicine, where his leadership roles included director at the Center for Molecular Biology and Gene Therapy.
More on Dr. Lilly
Michael B. Lilly, MD
Dr. Lilly's Clinical Interests
- Prostate Cancer
Request an Appointment with Dr. Lilly
New patients may call
MUSC Health Connection
Patient Referral Information
| Physicians call MEDULINE|